Cathie's Ark Logo
Exact Sciences Corp. Logo

ARKK Holdings of Exact Sciences Corp. (EXAS) - Updated Daily

Liquid BiopsyGenomicsGenetic Testing
Date
Direction
Shares
Fund Weight
Fund
September 6, 2023
SELL41.582k0.0436%ARKK
August 28, 2023
SELL29.684k0.0325%ARKK
August 25, 2023
SELL19.820k0.0216%ARKK
August 16, 2023
SELL78.164k0.0875%ARKK
August 11, 2023
SELL33.277k0.035%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
3.4%$12.00b
🏋🏿‍♂️Weight Rank In ARKK🌏Country
13🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
7$106.19
🎫ARK Ownership Percent
1.89%
Description
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com
Website
https://www.exactsciences.com/

Other ETFs That Hold EXAS

Ticker
NameWeight
ARKGARK Genomic Revolution ETF11.77%
ARKKARK Innovation ETF6.43%
XBISPDR® S&P Biotech ETF1.49%
AGNGGlobal X Aging Population ETF0.85%
LABUS&P Biotech Bull 3X Shares ETF0.209%

Research Notes and Commentary for EXAS

No Research Notes Found for EXAS